#### Ultra-low coverage genome-wide association study - insights 1

#### into gestational age using 17,844 embryo samples with 2

#### preimplantation genetic testing 3

4	
5	Shumin Li <sup>1,#</sup> , Bin Yan <sup>1,#</sup> , Thomas K.T. Li <sup>6,#</sup> , Jianliang Lu <sup>1</sup> , Yifan Gu <sup>4,5</sup> , Yueqiu Tan <sup>4,5</sup> ,
6	Fei Gong <sup>4,5</sup> , Tak-Wah Lam <sup>1</sup> , Pingyuan Xie <sup>2,3,*</sup> , Yuexuan Wang <sup>1,7,*</sup> , Ge Lin <sup>3,4,5,*</sup> ,
7	Ruibang Luo <sup>1,*</sup>
8	
9	<sup>1</sup> Department of Computer Science, The University of Hong Kong, Hong Kong,
10	China
11	<sup>2</sup> Hunan Normal University School of Medicine, Changsha, 410013, Hunan, China
12	<sup>3</sup> National Engineering and Research Center of Human Stem Cell, Changsha, Hunan,
13	China
14	<sup>4</sup> NHC Key Laboratory of Human Stem Cell and Reproductive Engineering, School of
15 16	Basic Medical Science, Institute of Reproductive and Stem Cell Engineering, Central South University Changsha 410008 Hunan China
17	<sup>5</sup> Clinical Research Center for Reproduction and Genetics in Hunan Province
18	Reproductive and Genetic Hospital of CITIC-Xiangva Changsha 410013 Hunan
19	China
20	<sup>6</sup> Department of Obstetrics & Gynecology Queen Mary Hospital The University of
21	Hong Kong, Hong Kong, China
22	<sup>7</sup> College of Computer Science and Technology. Zheijang University, Hangzhou
23	China
24	
25	<sup>#</sup> These authors contributed equally to this work
26	* To whom correspondence should be addressed: Ruibang Luo, Email:
27	rbluo@cs.hku.hk, Ge Lin, Email: linggf@hotmail.com, Yuexuan Wang, Email:
28	amywang@hku.hk, Pingyuan Xie, Email: plainxie192@126.com
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	

39

40 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 41 **Abstract**

Background: Very low coverage (0.1 to 1x) whole genome sequencing (WGS) has become a promising and affordable approach to discover genomic variants of human populations for Genome-Wide Association Study (GWAS). To support genetic screening using Preimplantation Genetic Testing (PGT) in a large population, the sequencing coverage goes below 0.1x to an ultra-low level. However, its feasibility and effectiveness for GWAS remains undetermined.

Methods: We devised a pipeline to process ultra-low coverage WGS data and benchmarked the accuracy of genotype imputation at the combination of different coverages below 0.1x and sample sizes from 2,000 to 16,000, using 17,844 embryo PGT with approximately 0.04x average coverage and the standard Chinese sample HG005 with known genotypes. We then applied the imputed genotypes of 1,744 transferred embryos who have gestational ages and complete follow-up records to GWAS.

**Results:** The accuracy of genotype imputation under ultra-low coverage can be improved by increasing the sample size and applying a set of filters. From 1,744 born embryos, we identified 11 genomic risk loci associated with gestational ages and 166 genes mapped to these loci according to positional, expression quantitative trait locus and chromatin interaction strategies. Among these mapped genes, *CRHBP*, *ICAM1* and *OXTR* were more frequently reported as preterm birth related. By joint analysis of gene expression data from previous studies, we constructed interrelationships of mainly

#### 62 CRHBP, ICAM1, PLAGL1, DNMT1, CNTLN, DKK1 and EGR2 with preterm birth,

63 infant disease and breast cancer.

64	Conclusions: This study not only demonstrates that ultra-low coverage WGS could
65	achieve relatively high accuracy of adequate genotype imputation and is capable of
66	GWAS, but also provides insights into uncovering genetic associations of gestational
67	age trait existed in the fetal embryo samples from Chinese or Eastern Asian populations.
68	
69	Keywords: Ultra-low coverage Whole Genome Sequencing, Imputation, Single
70	Nucleotide Polymorphisms, Genome-Wide Association Study, Gestational Age,
71	Preterm Birth
70	
72	
75	
74 75	
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	
87	
88	
89	
90	

### 96 Background

Detection and characterization of genetic variants associated with traits and diseases 97 are fundamental to the study of human genetics. Genome-Wide Association Study 98 99 (GWAS) is an approach widely used in genetic research that aims to decode the associations of specific genetic variations with particular diseases or traits in sample 100 101 populations. In the past decade, GWAS has facilitated discovery of over one hundred thousand variants associated with complex traits in human (1). Whole-genome 102 sequencing (WGS) has emerged as a dominant technology in GWAS because it enables 103 one to generate a comprehensive view of the genomic variation landscape for not only 104 a specific trait but also for common diseases. Thus, WGS-based approaches hold a 105 significant advantage over genome-wide genotyping arrays or exome sequencing in the 106 107 analysis of complete genetic variations. However, with a fixed budget, the high cost of sequencing many DNA samples is a limitation for GWAS (2-4). Recently, to reduce the 108 cost of sequencing, a number of low (0.5-1x) or extremely low-coverage (0.1-0.5x)109 WGS has been carried out as an alternative method of genotyping (2, 5, 6). It is, 110 however, unclear whether ultra-low coverage WGS (ulcWGS) below 0.1x data can 111 capture enriched genetic variations across the entire allele frequency (AF) spectrum. 112 When considering a balance between number of samples sequenced and sequencing 113 read coverage, effective genotype imputation could provide more authentic DNA 114 variants that would be helpful for genetic research. 115

Genotype imputation can be used to infer missing genotypes and to increase theaccuracy of detecting genetic variants, such as single nucleotide polymorphisms (SNPs).

In general, performance of genotype imputation is largely affected by sample size, 118 119 sequencing coverage, analysis methods, and other parameters (7). A main challenge to 120 use very low coverage WGS is how to achieve an adequately accurate imputation for downstream analyses. Previous attempts have shown the efficiency of low coverage 121 WGS, for example, a high  $r^2$  of imputation accuracy observed by using 10 low coverage 122 123 WGS ( $\sim 0.5x$ ) as compared to known genotypes (6). Pasaniuc et al. reported that the GWAS signals obtained from using 909 whole-exome sequencing (~0.24x) are 124 comparable to using genotyping array (2). Gilly et al. found that more true association 125 signals were identified by WGS ( $\sim 1.0x$ ) than the traditional array-based study (5). 126 Using ulcWGS (0.06x-0.1x) with 141,431 samples from a Chinese genomic study, the 127 accuracy of imputed genotypes reached 0.71 (8). Even though the distribution of 128 genetic background from large number of samples is expected to compensate for the 129 low sequencing coverages, it has never been determined how many samples are needed 130 131 to achieve a relatively high accuracy. More importantly, lack of comparative data with coverages less than 0.05x results in the limited application of ulcWGS to GWAS. 132

Gestational age is an important complex trait associated with biological processes and human disease. Biologically, gestational duration plays a vital role in both mental and physical health of children at an age of five-year-old (9). Gestational age shorter than 37 weeks is categorized as Preterm Birth (PTB). Previous studies found the contribution of both the maternal and fetal genomes to variation of gestational ages (10-12). However, they focused on European and African samples by involving few samples from Chinese or Eastern Asian ancestries. Overall, biological mechanisms

140 underlying variation of gestational durations remain unclear, primarily because 141 insufficient maternal or fetal genotypes with widespread gestational ages have been 142 collected (13). Recently, Preimplantation Genetic Testing (PGT) with trophectoderm biopsy for embryo aneuploidy screening has become a common practice in *in vitro* 143 fertilization (14, 15), and poses as an expectant source of genotypes for GWAS. 144 145 However, if the average sequencing coverage of PGT is even lower than the lowest levels that have been reported in GWAS so far, it is necessary to examine whether such 146 PGT datasets are appropriately applied to GWAS. 147

In this study, we devised a pipeline for analyzing and applying the ulcWGS of 148 17,844 embryo samples for GWAS. Our result shows that a large sample size is 149 effective to increase the accuracy of genotype imputation even at an ultra-low coverage. 150 151 Furthermore, using the imputed genotypes of 1,744 embryos that were successfully transferred and born with a widespread of gestational ages, we demonstrate the power 152 153 of using ulcWGS in GWAS and provides insights into understanding genetic association of gestational age in embryos acquired from Chinese and East Asians. 154 Refreshing the lowest coverage used in GWAS, our finding also provides a foundation 155 for exploring the utilization of an even lower coverage for dissecting genotype-156 phenotype associations. 157

158

159 Methods

160 Samples and sequencing coverage

161 The whole PGT dataset of 17,844 embryos was from the Clinical Research Center for
162 Reproduction and Genetics in Hunan Province, Reproductive and Genetic Hospital of

163	China International Trust Investment Corporation - Xiangya. The protocol of embryo
164	culture and biopsy was published in a related study (16). Three WGA kits were applied
165	to the biopsied TE cells by following the manufactures' guides, including REPLI-g
166	Mini Kit (called MDA), WGA4 GenomePlex Single Cell Whole Genome
167	Amplification Kit (called dop-PCR) and Rubicon Genomics PicoPlex Single Cell
168	Whole Genome Amplification Kit (called PicoPlex). A 1-2 $\mu$ g of the WGA product was
169	subjected to library construction and sequencing on the four platforms, including BGI-
170	Seq 500, Illumina MiSeq, Ion Proton, Ion Torrent (Additional file 1: Table S2).

171

#### 172 Study design

We developed a three-step pipeline to carry out genotype imputation using ulcWGS 173 174 data and to perform GWAS of the detected SNPs (Fig. 1). Firstly, the raw reads of the 17,844 embryo samples were aligned to the hs37d5 reference genome. Sequencing 175 coverage of these embryo samples displays a distribution with an average coverage 176 0.04x (Additional file 3: Figure S1). To our best knowledge, it is below the coverage of 177 any dataset used previously for genotype imputation. After removing potential PCR 178 179 duplicates, the aligned reads were used to call population SNPs. Secondly, we 180 conducted genotype imputation on each individual sample at the called population SNPs and assessed the genotyping accuracy based on the standard Chinese sample 181 HG005 with known genotypes from GIAB (Genome in a Bottle, NIST)(17). Last, we 182 183 applied the imputed genotypes from 1,744 born embryos with complete follow-up

- 184 records to GWAS and explored biological associations between the genetic variants
- 185 detected in the born embryos and their gestational ages.
- 186

#### 187 Sequencing read processing and alignment

In the first step of Fig. 1, the raw reads of the PGT samples were delivered in two types, fastq or BAM. For BAM data, we used bedtools (18) to extract the raw reads into single-end fastq files. The raw reads of each sample were then aligned to the hs37d5 reference genome using BWA (19). BWA-mem was applied to samples sequenced by the Ion Torrent with longer reads and "bwa aln" was used for the rest of the samples with shorter reads. Samtools rmdup (20) was used to remove the potential PCR duplicates.

195

#### 196 **Population SNP calling**

In the population SNP calling stage, we modified the method of Liu et al. (8). The first stage is to use log-likelihood estimation for AF estimation, and the second stage is to use log-likelihood ratio test for determining allelic types. More details are described in Additional file 2: Supplementary Methods.

201 SNP calls of the raw population were filtered following the rules, 1) calls that 202 overlapped with the 35-kmer problematic alignment regions in hs37d5 were removed 203 (21); 2) calls that overlapped with regions with ENCODE mappability uniqueness 204 score unequal to 1 were removed (22), tool "bigWigToBedGraph" used afterward to 205 convert the bigwig into bed format) (23).

#### 207 Genotype imputation

We used STITCH (24) version 1.5.7 for genotype imputation. The ancestral haplotypes 208 number k was set as 20, the assumed number of generations nGen was set to 2000, and 209 the reads were binned into windows with gridWindowSize 10000. The diploid mode in 210 STITCH was used. Although using a reference panel is optional in STITCH, we used 211 the IMPUTE2 1000 genome haplotypes phase 1 reference panel as it improves the 212 accuracy of imputation when the sample size is small. With sample size larger than 213 10,000, the improvement was not significant. All parameters were optimized by 214 maximizing the  $r^2$  of the estimated AFs between imputation and population SNP 215 calling in a randomly chosen 5 Mbp genomic region (chr3:180-185Mbp). When 216 applying STITCH to the whole genome, we divided the genome into 5 Mbp windows 217 with a 500 Kbp overlap between two windows. 218

For benchmarking, seqtk was used to subsample the HG005 Illumina WGS raw reads to 0.01x-0.1x (Paired-end 250bp, 300-fold). We aligned the reads to hs37d5 by using the same pipeline as used in the embryo samples. Because a computer takes a few years to impute whole genome with tens of thousands of samples, we worked on only chromosome 1, the longest one in human. The genotype imputation was benchmarked according to 80 combinations of the 10-scale coverages of HG005 with 8 sizes of our samples from 2,000 to 16,000, respectively.

All bi-allelic SNPs with MAF  $\geq$  0.01 found in chromosome 1 with the population SNP calling from the 17,844 samples are included for genotype imputation. We used the 167,814 SNPs both in our SNP callset and HG005 known genotypes for

229	benchmarking. The imputed genotypes were compared to the truth released by GIAB
230	for estimating the imputation accuracy. Then, genotype imputation was applied to all
231	17,844 embryo datasets at the 31,622,332 bi-allelic sites with MAF $\geq 0.01$ found in
232	population SNP calling. The entire imputation process spent 19 days and used 15
233	machines with 16 cores (two 8-core Intel Xeon Silver 4108 CPU). Two filters "INFO
234	score $\geq$ 0.4 and HWE <i>p</i> -value >1e-6" were applied to select the imputed genotypes.

235

#### **Genome-wide association study (GWAS)**

To conduct GWAS, we used score statistics (25) that is implemented in ANGSD (26). 237 Variants satisfying four conditions were selected as inputs, including 1) known in 238 dbSNP150, 2) MAF > 0.01, 3) INFO score  $\geq$  0.4, and 4) HWE *p*-value > 1e-6. To 239 remove biases, we specified 16 covariates for ANGSD, 8 most significant principal 240 components calculated from the inputs of PCA (Additional file 2: Supplementary 241 242 Methods), and 8 clinical records including maternal age, maternal BMI, fetal sex, either parent with single-gene disease, either parent with chromosome abnormality, multiple 243 pregnancy, preeclampsia and gestational diabetes of mellitus. Except the default 244 parameters, we set *minHigh* to 15 (requiring at least 15 high credible genotypes from 245 the input) instead of 10 to achieve better accuracy with a large sample size. ANGSD 246 did not create an output beta-coefficient, so we followed the ideas of Skotte et al. (25) 247 by incorporating the genotype probabilities and all 16 covariates into a linear regression 248 model, with the gestational age as a response variable. The effect size was calculated 249 by the coefficient of genotypes. 250

#### 251 Independent SNPs and genomic risk loci

252	The significant SNPs from our GWAS were mapped to genomic risk loci using FUMA
253	pipeline (27) and the LD information of 1000G EAS variants (28). We first defined
254	"independent significant SNP", a SNP that meets genome-wide significance level
255	(p value $\leq 4.515e - 8$ ) and is independent of other significant SNPs (with LD r <sup>2</sup> <
256	0.6). FUMA also generated a set of lead SNPs with low LD and with other ( $r^2 < 0.1$ )
257	from the independent significant SNPs. The genomic risk loci were identified by
258	starting from these lead SNPs and through iteratively merging related genomic regions
259	to them according to FUMA's rules.
260	Also, the FUMA pipeline sorted out a set of candidate SNPs from our inputs
261	that meets one of two conditions, 1) the independent significant SNPs and 2) SNPs that
262	are linked to the independent significant SNPs (with LD $r^2 \ge 0.6$ ). For condition 2,
263	the SNPs can be from our imputed genotypes if p value below 0.05 or from the reference
264	panel of 1000G EAS. ANNOVAR was used to annotate the candidate SNPs (29).
265	
266	Functional annotation of the mapped genes
267	DAVID online tool (30) was used to analyze the enrichment of Gene Ontology (GO)
268	biological processes and KEGG pathways for the coding genes mapped to the risk
269	loci.
270	

270

## **Gene mapping**

272 We used three gene-mapping strategies provided by FUMA (27), including positional,

273 expression quantitative trait locus (eQTL) and chromatin interaction. For positional

274	mapping, ANNOVAR annotations were used. The candidate SNPs were mapped to the
275	nearest genes within a maximum 10 Kbp distance. For eQTL mapping, expression data
276	of all tissue types in GTEv6, GTEv7, and GTEv8 (31) were used. We required False
277	Discovery Rate (FDR) < 0.05 and p value <0.001 for a valid eQTL mapping. All
278	chromatin interaction data in FUMA were used (32-35). The promoter was set to
279	upstream 2000 bp to downstream 500 bp of transcriptional starting sites. We required
280	FDR < 1e-6 for a valid chromatin interaction mapping.

281

#### 282 Analysis of genome-wide mRNA expression data

We first extracted the genome-wide microarray and RNA-seq data of human mRNA 283 284 expression from GEO/NCBI database. The mRNA data includes three subsets in 285 maternal PTB, infant PTB and breast cancer (Additional file 1: Table S8). Based on the normalized expression data provided by the database, we analyzed differentially 286 expressed genes (DEGs) between different conditions, including 1) PTB vs. normal 287 288 term, 2) BPD or sepsis vs. infant without BPD or sepsis, and 3) breast cancer vs. control samples. For microarray platform-based data, we used the *limma* package in R 289 programming language and conducted empirical Bayes moderated t-test. DEGs were 290 291 detected with a fold change above 1.5 and p value below 0.05. For RNA-seq data with raw counts, we utilized the Edge-R method to identify DEGs. The DEGs are listed in 292 Additional file 1: Table S9. 293

#### 295 **Results**

# Benchmarking genotype imputation using the ultra-low coverage sequencing data of 17,844 embryos and HG005

We estimated the accuracy of the imputed genotypes from the SNPs of chromosome 1 298 both called in our 17,844 samples and the known genotypes in HG005. The genotype 299 300 imputation was benchmarked according to 80 combinations of the 10-scale coverages of HG005 with 8 sizes of our samples. A monotonic increase in accuracy with 301 sequencing coverage was observed (Fig. 2a), consistent with previous studies (2, 24). 302 The accuracy for sample size of 2,000 stayed at around 0.48 under all sequencing 303 coverages. But for a larger sample size of 16,000, its accuracy increased from 0.48 at 304 0.01x to 0.66 at 0.1x. This result suggests that at ultra-low coverages, increase in sample 305 size could obtain higher accuracy (Additional file 1: Table S1). In general, a lower 306 coverage with a larger sample size results in better performance than a higher coverage 307 with a smaller sample size. For example, the genotype accuracy at 0.05x with 14,000 308 samples versus 0.1x with 4,000 embryos was 0.61 versus 0.55. A larger sample number 309 is therefore more efficient in optimizing genotype imputation than increasing sequence 310 coverage. It is also noticed that at the two lowest coverages in our experiments, the 311 contribution of increasing sample size was not significant and the accuracy plateaued 312 at 0.52 (0.01x) and 0.55 (0.02x). Using the same datasets, we evaluated allele accuracy 313 that relaxed zygosity correctness from genotype accuracy. The corresponding 314 315 accuracies were much better (increased to 0.7 and higher) while maintaining the same trend with increasing sample size and coverage (Fig. 2b). Therefore, when the 316

317 genotypes are incorrectly imputed for some SNPs, the non-reference allele could be318 correctly detected.

We next examined several important quality metrics that are widely used to filter 319 falsely imputed genotypes. The INFO score of IMPUTE2 style (36) denotes the 320 certainty of an imputed genotype and has been accepted as a quality metric of 321 322 imputation. For a combination of 0.04x coverage with 16,000 samples, we benchmarked ten different INFO score thresholds from 0.1 to 1.0 and detected 323 corresponding SNPs. As increase in the INFO scores, we observed a consistent increase 324 in genotype accuracy from ~0.60 to 0.99, but a rapid decrease in number of SNPs that 325 meet these thresholds (Fig. 3a). Thus, INFO score could act as an effective metric to 326 327 evaluate the accuracies at ultra-low coverage, but its thresholds should be meticulously chosen in order to retain sufficient SNPs. Effect of MAF scores on genotype accuracy 328 329 of HG005 were then tested as a potential metric. We divided the genotyping results at 330 different sequencing coverages (sample size fixed to 16,000) into bins of MAF ranges (0.01 MAF a bin) and calculated the genotype accuracy each bin. The genotype 331 accuracy increased rapidly from MAF 0 to 0.05 and reached a turning point at 0.05. 332 After this point, the accuracy became slow increasing (Fig. 3b). However, even for the 333 most common SNPs (MAF  $0.4 \sim 0.5$ ), the accuracy was converged at  $\sim 70\%$ . The 334 accuracy of the two lowest coverages 0.01x and 0.02x fluctuated especially at low MAF 335 336 cutoffs. Because such fluctuation was not observed during INFO testing, MAF might not be a reliable metric to change genotype accuracy at ultra-low coverage. In 337 338 subsequent analyses, we followed the common practice to use SNPs with MAF  $\geq 0.01$ 

339	for GWAS. Finally, we combined HWE p-values with INFO scores as a filter but
340	without losing too many SNPs. HWE p-values could evaluate the probability of the
341	imputed genotype at a certain SNP that is significantly different from the expectations
342	by Hardy-Weinberg Equilibrium. We summarized the genotype accuracy of different
343	combinations of INFO scores and HWE <i>p</i> -value cutoffs in Table 1. When INFO scores
344	were set above 0.4, the accuracies of genotype and allele were 70.0% and 83.4%,
345	respectively, with 48,176 SNPs left. The "INFO score $\geq 0.4$ and HWE <i>p</i> -value >1e-6"
346	resulted in an increased accuracy 71.5%, with 28773 SNPs left. Thus, our GWAS
347	utilized this setting, "INFO score $\geq 0.4$ and HWE <i>p</i> -value >1e-6" as filtering criteria.
348	To summarize our benchmarking results for future study on ulcWGS, we built a
349	regression model (Formula 1) to calculate the expected genotype accuracy using
350	sequencing coverage and sample size as inputs.
	$acc = 2.227 * c + 8.937e^{-6} * s + 0.494 \ (c \ge 0.01, s \ge 4000)$ (1)
351	where $acc$ is the expected genotype accuracy, $c$ denotes the sequencing coverage, $s$
352	denotes the sample size. The model has a $r^2$ of 0.874 (Additional file 3: Figure S2).
353	
354	GWAS of gestational ages using 1,744 born embryos

With the solid foundation laid out in the previous section, we have obtained sufficient good quality SNPs for GWAS. Among the 17,844 sequenced embryos, 1,744 were transferred and gave birth to a baby. The gestational age of all 1,744 born embryos are well documented and thus were chosen for biological associated study. We revised the population SNP calling method used in Liu et al. (8). A total of 151,793,444 SNPs were detected and of 141,718,305 are bi-allelic. The MAF spectrum bi-allelic novel and

361	known variants in dbSNPv150 (37), 1000G (28) and gnomAD (38) is shown in
362	Additional file 3: Figure S3a. The transitions/transversions ratio for "all bi-allelic SNPs"
363	and "bi-allelic SNPs known in dbSNPv150" were 3.05 and 3.58, respectively. Pearson
364	correlation coefficient of the non-reference AFs between the 301 Chinese samples in
365	1000G (so-called 1000G CHN (28)) and the corresponding SNPs obtained in our
366	dataset was 0.986 (Additional file 3: Figure S3b). This result supports a strong
367	correlation between the two datasets, and high confidence of the known variants used
368	in our analysis. We also performed genotype imputation at bi-allelic population SNPs
369	with MAF $\geq$ 0.01. Pearson correlation coefficient was 0.985, showing a high
370	consistency between the estimated AFs in population SNP calling and in imputation.

Three different whole genome amplification (WGA) methods and four different 371 sequencing platforms were used in the PGT dataset (Additional file 1: Table S2). It is 372 not uncommon that large number of samples may use multiple sequencing platforms 373 374 and WGA. Removing these unrelated covariates from GWAS as much as possible is essential especially when the sequencing coverage is ultra-low. Such covariates should 375 be detected and disregarded in GWAS. We applied Principal Component Analysis (PCA) 376 to the imputed genotypes of SNPs with MAF  $\geq$  0.05 among all 17,844 embryo samples 377 378 (Additional file 2: Supplementary Methods, Additional file 3: Figure S4a). The first and second principal components distinguish the differences of sequencing platforms 379 (Additional file 3: Figure S4b) and of WGA methods (Additional file 3: Figure S4c). 380 381 Therefore, we used the top eight principal components and eight other clinical records as covariates in GWAS. PCA was also applied to the GWAS samples and the top 382

383 principal components were included in the subsequent analyses as covariates for384 removing the biases.

We used the state-of-the-art one-stage GWAS strategy (39) to analyze the 1,107,198 imputed SNPs in the 1,744 transferred and born embryo samples with complete follow-up records. The distribution of gestational ages shown in Additional file 3: Figure S5 include 162 preterm deliveries (gestational age < 37 weeks), 42 early preterm deliveries (gestational age <34 weeks), and 8 very early preterm deliveries (gestational age <28 weeks). The gestational ages were standardized by z-score and incorporated as a quantitative trait.

A total 1,107, 198 SNPs with imputed genotypes were selected for GWAS that 392 are in accord with, 1) MAF  $\geq$  0.01, 2) known in dbSNPv150, and 3) passed the filter 393 "INFO score  $\geq 0.4$  and HWE *p*-value >1e-6". The Q-Q plot shows a large deviation of 394 the observed p values from the null hypothesis (Additional file 3: Figure S6). The 395 linkage disequilibrium score regression (LDSC) software package (40) with 1000G 396 EAS reference was used to estimate  $\lambda_{GC} = 0.992$ , mean  $\chi^2 = 1.012$ . The LD score 397 regression intercept was 0.952, standard error = 0.021, indicating that the population 398 stratification and other factors were well-controlled. We identified 40 significant SNPs 399 satisfying Bonferroni-corrected significant levels of 4.515e-8. The Manhattan plot 400 shows the distribution of the detected SNPs cross all chromosomes (Fig. 4a, Additional 401 402 file 1: Table S3).

403 We used FUMA (27) pipeline for GWAS downstream analysis. First, FUMA 404 generated a set of candidate SNPs and the 11 independent SNPs (Additional file 1:

405	Table S4). By annotation, most of the SNPs are located and enriched in intergenic and
406	intronic regions (Fig. 4b), which is similar to the previous study (41). Specifically, there
407	are 11 SNPs located in exons (0.8% of total), and 4 of them are non-synonymous SNPs
408	(Additional file 1: Table S5). Additionally, we observed the distribution of regulatory
409	elements and chromatin states with the candidate SNPs (Additional file 3: Figure S7).
410	According to RegulomeDB scores assigned to each candidate SNP, 1.09% SNPs were
411	classified as likely to affect regulator binding (score 2a and 2b) and 0.21% as likely to
412	affect regulator binding and linked to expression of a gene target (score 1d and 1f).
413	These proportions of SNPs hold a relatively high likelihood to affect the regulatory
414	elements along noncoding regions. Second, we identified 11 leading SNPs from their
415	corresponding genomic risk loci by FUMA. Fig. 4e shows the DNA length, number of
416	SNPs and mapped genes of these risk loci. The zoom in locus plot of the 11 risk loci
417	are shown in Additional file 3: Figure S8. Of 4 risk loci were reported to be associated
418	with refractive astigmatism, adolescent idiopathic scoliosis, glomerular filtration rate,
419	among others, indicating a possible connection of these diseases or traits with PTB
420	(Additional file 1: Table S6).

By integrating strategies positional, eQTL and chromatin interaction mappings, we identified a total of 166 genes mapped to the 11 risk loci, including 48 and 19 genes from two and three strategies, respectively (Fig. 4c, Additional file 1: Table S7). There were 24 genes detected within or less than 10 Kbp from the candidate SNPs and 7 of them were shown in Fig. 4a based on the location of the genomic risk loci. Importantly, *CNTLN* was reported as a PTB related gene (42), and *PIN1* involves inhibition of breast

$7 \rightarrow 1$
cancer (43). A Circos plot snows the graphic distribution of the mapped genes via eQ11
8 and chromatin interaction, and their links with the genomic risk loci (Fig. 4d). The
9 breakdown of each chromosome is shown in Additional file 3: Figure S9. Even though
0 not within any risk loci, <i>CRHBP</i> was linked through chromatin interaction mapping to
1 two loci, chr5:75101342-75164623 and chr5:78251511-78271282. Enrichmen
2 analysis of DEGs in 30 tissue types in GTEx v8 (44) exhibits significant overexpression
of the mapped genes in both ovary and uterus (Additional file 3: Figure S10a). The
4 gene-set enrichment analysis also indicates their association with the immune system
5 breast cancer and transcriptional regulation (Additional file 3: Figure S10b).
6
7 Association of the 166 mapped genes from GWAS with preterm birth
8 infant disease and breast cancer
9 GWAS of gestational age related PTB has been implicated in biological functions that
0 include immune response, inflammatory response, and coagulation factors (11, 45-47)
1 We compared our 166 mapped genes with reported PTB markers by collection of 8
2 published resources, here classed to 3 PTB sets, including dbPTB from Sheikh et al
3 (48) and Uzun et al (49), PTB-merged from 5 data resources (10), and PNAS-identified
4 DEGs of PTB in 2019 (10). We found that CRHBP, EMR1, ICAM1, MBL2, OXTR, and
TUDS(4) = 1
5 <i>THBS4</i> have been reported in at least 2 PTB sets. Specifically, <i>ICAMT</i> was present if
all 3 sets and 6 data resources, and both <i>CRHBP</i> and <i>OXTR</i> in 5 resources (Additional
<ul> <li><i>THBS4</i> have been reported in at least 2 PTB sets. Specifically, <i>TCAMT</i> was present if</li> <li>all 3 sets and 6 data resources, and both <i>CRHBP</i> and <i>OXTR</i> in 5 resources (Additional</li> <li>file 1: Table S7). In addition, there were 8 genes overlapped with 1 PTB set (Fig. 5a)</li> </ul>
<ul> <li><i>THBS4</i> have been reported in at least 2 PTB sets. Specifically, <i>TCAMT</i> was present if</li> <li>all 3 sets and 6 data resources, and both <i>CRHBP</i> and <i>OXTR</i> in 5 resources (Additional</li> <li>file 1: Table S7). In addition, there were 8 genes overlapped with 1 PTB set (Fig. 5a)</li> <li>This result pinpoints a relationship of the detected risk loci with PTB, and possible roles</li> </ul>

450	however, only 50 were frequently recognized by at least 5 data resources, hereafter
451	referred to as PTB marker genes (Additional file 1: Table S7). The 50-PTB marker set
452	was significantly enriched with inflammatory and immune response related processes
453	or pathways (Fig. 5b). Similarly, those PTB genes that overlapped with 3 or 4 resources
454	mainly participate in the same biological functions. The PTB-related genes listed at Fig.
455	5a involve immune response (EMR1, ICAM1, PTPRZ1 and MBL2), inflammatory
456	response (CRHBP, ICAM1, PTPRZ1 and MBL2), coagulation (MBL2), apoptosis
457	(PLAGL1) and cell adhesion (ICAM1 and THBS4), emphasizing their associations with
458	PTB.

To determine the relationship between the mapped genes and PTB, we first 459 analyzed the DEGs between maternal PTB and normal term birth based on six 460 published datasets of genome-wide gene expression (Additional file 1: Tables S8 and 461 S9). Significant overexpression of CRHBP and OXTR were identified in two datasets, 462 while overexpressed (ICAM1, EGR2, and PLAGL1) and underexpressed (THBS4) 463 genes were present in one dataset (Table 2). Another DKK1 expressed higher levels 464 above 2.0-fold in two datasets, suggesting its importance in PTB. Then, we analyzed 465 four infant PTB datasets of gene expression, and found differentially increased 466 expression of ICAM1, CRHBP, DKK1, EGR2, and PLAGL1, consistent with maternal 467 PTB. In contrast, significantly underexpression of THBS4, PIN1 and GCNT4 was 468 commonly detected by maternal and infant subgroups (Table 2). It is also noticed that 469 470 DNMT1 shows increased expression in both fetal and maternal groups (Table 2). DNA methylation was suggested to involve generation of early PTB (10); however, the role 471

of *DNMT1* as a DNA methyltransferase in PTB has not been determined yet. This
analysis provides evidence that these mapped DEGs above including *DNMT1* are
associated with both maternal and infant PTB. Relatively, *OXTR* seems to be related to
only maternal factor. A heatmap of mRNA expression shows clustering of 6 expression
profile cross PTB and normal term conditions (Fig. 5c). Two clusters display distinct
expression patterns of these PTB genes.

It is well known that bronchopulmonary dysplasia (BPD) is the most common 478 respiratory disorder among children born preterm (50, 51). The pathogenesis of BPD 479 involves multiple prenatal and postnatal mechanisms affecting the development of 480 immature lung. Also, neonatal sepsis is associated with severe morbidity and mortality 481 during the neonatal stage. The incidence of late-onset sepsis increases with increase in 482 survival rate of preterm and low weight babies (52). Thus, we examined the possible 483 relationship of the 166 genes with infant BPD and sepsis by analyzing gene expression 484 485 data derived from samples of preterm infants (Additional file 1: Table S8). We first identified differentially increased expression of CRHBP, ICAM1 and EGR2 under PTB 486 of maternal & infant and BPD conditions, but differentially decreased expression of 487 DKK1 (Table 2). Under sepsis condition, differentially overexpressed CNTLN, ICAM1, 488 and *PLAGL1* in PTB were consistently observed. By contrast, *GCNT4* expression was 489 always significantly decreased under maternal and infant subpopulations. The gene 490 clustering shows diversity of gene expression across different samples with infant PTB; 491 however, these up-regulated genes were grouped together (Fig. 5d), supporting the idea 492 that BPD or sepsis induces the change in these PTB genes. 493

494	Breast cancer is one of the most frequently diagnosed malignancies observed
495	during pregnancy. It often presents characteristics of high malignancy and are hormone
496	receptor negative like Estrogen receptor (ER)-, HER2+ or triple negative breast cancer
497	(TNBC). We collected gene expression data mainly presenting three subtypes of breast
498	cancer, TNBC, HER2+ and ER or Progesterone receptor (PR) (Additional file 1: Table
499	S8). By analysis of DEGs, we detected the expression of PTB related genes DKK1,
500	ICAM1, DKK1, EGR2, PLAGL1, GCNT4 and THBS4 in all three subtypes. Increased
501	ICAM1 and decreased PLAGL1 were consistently identified in these datasets (Table 2).
502	In fact, ICAM1 has been reported as TNBC markers (53) and acts as prognostic
503	molecule of breast cancer (54). Both ICAM1 and DKK1 could increase expression in
504	TNBC cells (55). However, other PTB related genes do not display similar changes in
505	expression under the cancer subtypes. For example, OXTR was detected by only one
506	dataset of ER+/-, while CRHBP, EMR1, PIN1 and MBL2 were not found among any of
507	the subtypes. Conversely, underexpression of <i>PLAGL1</i> and <i>GCNT4</i> were found in all
508	three types of breast cancer. In addition, overexpression of DNMT1 was observed in
509	TNBC and HER2+ subtypes, that validates its oncogenic roles in breast cancer and drug
510	target of TNBC (56, 57).

511 To identify further interactions between the selected PTB genes from Table 2 and 512 the top 50 PTB markers, we calculated Pearson correlation coefficient by comparing 513 their gene expression of maternal and infant PTB, BPD and sepsis subsets, respectively. 514 We built the corresponding co-expression networks of the PTB genes (Additional file 515 3: Figure S11). Clearly, the co-expressed genes involve immune and inflammatory

516	responses, coagulation, as well as apoptosis, angiogenesis, among others. We then
517	constructed the networks cross different subpopulations. As shown in Fig. 6a, the PTB
518	genes could involve both maternal and infant PTB processes, especially ICAM1,
519	PLAGL1, EGR2 and CRHBP that link to TLR4, a known preterm marker associated
520	with immune and inflammatory processes (58). Similarly, co-expression interactions of
521	these genes with the top PTB markers were observed under maternal PTB and infant
522	BPD (Fig. 6b). Both OXTR and PIN1 only display gene correlations under maternal
523	PTB, whereas MBL2 only correlates under infant PTB. This analysis indicates that the
524	predicted PTB-related genes including ICAM1, CRHBP, PLAGL1, EGR2, CNTLN, and
525	DKK1, play an important role in preforming biological activities associated with PTB,
526	infant disease, possibly breast cancer, due to the gestational age-induced.

527

#### 528 **Discussion**

Low or very low coverage sequencing data have been increasingly used in discovery of 529 genetic variation and GWAS. However, if the coverages are further decreased to 530 extremely ultra-low levels, how many samples are required to obtain a relatively high 531 accuracy of genotype, and whether these samples can be appropriately applied to 532 533 GWAS. To address this challenge, we used 17,844 PGT datasets of embryo samples 534 with an average of 0.04x coverage and achieved genotype imputation performance comparable to those using low coverage samples. We first demonstrate that increase in 535 number of ulcWGS samples is more efficient than changing sequencing coverages and 536 indicates the ability of such ultra-low coverage PGT samples to obtain adequate 537 accuracy of phenotypes. Furthermore, we found that INFO score and HWE p-value are 538

effective to act as filters to improve the accuracy at ultra-low coverages while meanwhile keep enough SNPs for downstream analyses. To our best knowledge, the samples used in this study hold the lowest average WGS coverage for GWAS so far, and our study provides a framework for guiding other researchers who work on ulcWGS data.

544 Gestational age is a multi-factor phenotype involved in maternal and fetal biological activities (59). To investigate effects of the fetal genome on gestational age, 545 we used the imputed genotypes of 1,744 born embryo samples, a cohort of samples who 546 successfully gave birth after in vitro fertilization. From the 166 genes mapped to the 11 547 genomic risk loci, we identified a set of the PTB-related genes that were previously 548 reported (12, 59). CRHBP, ICAMI, and OXTR are primary representative genes 549 showing evidence of genetic association with gestational age among our samples. 550 CRHBP is an important gene in maternal and fetal gestation that could regulate the 551 552 pregnancy length by increasing/decreasing the concentration of CRH (60, 61). ICAMI involves disease induced PTB during pregnancy (62-64). Oxytocin signaling is 553 mediated by Oxytocin receptor (OXTR), which is related to gestational age (65). We 554 validated these predicted PTB genes by analysis of DEGs from maternal and infant 555 PTB subpopulations. 556

557 PTB is neonatal birth occurring before 37 weeks of gestation age and is a leading 558 cause of infant morbidity and mortality. Understanding of genetic and molecular 559 mechanisms of PTB and its association with gestation duration is currently insufficient. 560 Recently, Zhang et al. reported replicable loci in six genes (*EBF1*, *EEFSEC*, *AGTR2*,

WNT4, ADCY5 and RAP2C) associated with gestational duration (12). This study 561 562 identified 3 genes (EBF1, EEFSEC and AGTR2) strongly associated with PTB in a European ancestry cohort of 43,568 women. However, we did not detect such 6 genes 563 from the reported PTB markers and only identified them as DEGs from few published 564 datasets of PTB. This could be due to the heterogeneous sources of samples used in 565 566 different PTB studies or be explained in part by the genetic complexity of incomplete gestation induced PTB complications. Here, we collected almost 2,000 PTB-related 567 genes from previous PTB studies. The differences in study design, source and subtype 568 of samples, and statistical methods would be important factors that could account for 569 the diversity of PTB variants and genes among the various studies. Considering the 570 possible association of PTB with other traits, we compared differential gene programs 571 on multiple phenotypes between mother and infant reported in previous studies, and 572 demonstrated a high risk of CRHBP, ICAM1, DNMT1, CNTLN, PLAGL1, DKK1 and 573 574 EGR2 with PTB among our sample cohorts of Chinese or Eastern Asian ancestry. To support this finding, we reconstructed co-expressive networks linking the PTB-related 575 genes in GWAS with the reported PTB markers. Indeed, the correlated PTB genes are 576 mainly involved in immune & inflammation related processes and signaling pathways, 577 as well as coagulation factors. Thus, these findings have biological implications for 578 dissecting genetic associations of gestational factors with disease or traits in different 579 580 human ancestries.

581 Pregnancy is associated with an increased risk of developing breast cancer (66).
582 Although several reports indirectly described relationship between breast cancer and

PTB (67), evidence is still lacking. To determine whether a correlation exists between 583 584 PTB women and breast cancer pathogenesis, we compared differential expression of the PTB related genes in PTB samples and three subtypes of hormone receptor-related 585 breast cancer samples. Although several DEGs were found in both PTB and cancer 586 587 subtypes, their expression patterns are not consistent. It perhaps is because of different 588 subtype of samples derived from heterogeneous populations, as well as different phenotypes involved in the analyses. Nevertheless, our data provides additional 589 evidence that PTB might be related with breast cancer hormone-related subtypes. A 590 graphic overview of our results is summarized in Fig. 6c. We proposed interplays of 591 gestational age with PTB, fetal disease and breast cancer. The representative PTB genes 592 CRHBP, ICAM1, THBS4, DNMT1, CNTLN, PLAGL1, DKK1 and EGR2 are likely 593 associated with these phenotypes by targeting immune and inflammatory response, 594 coagulation, and cell adhesion. 595

#### 596 **Conclusions**

This study benchmarked the ability of ulcWGS to be used for genotype imputation. As 597 the first study using a large cohort of human embryo samples with ulcWGS, we 598 demonstrate its power and effectiveness in GWAS. We detected 40 significant SNPs 599 and 11 genomic risk loci that contains independent significant SNPs and are associated 600 with gestational age. From 166 genes mapped to the risk loci. We establish 601 interrelationships between the mapped genes and maternal or infant diseases and 602 provide insights into understanding the genetic associations of gestational ages. Our 603 findings should expand current GWAS related to gestational duration and preterm trait 604

by including Chinese and East Asian samples and would therefore be helpful to futureresearch.

607

#### 608 Supplementary Information

609

610 Additional file 1: Table S1. Genotype imputation performance at different ultra-low coverages and sample sizes. Table S2. WGA methods and sequencing platforms used 611 612 in the PGT experiments. Table S3. The summary of 40 significant SNPs satisfying Bonferroni-corrected significant levels of 4.526e-8 from 1,744 embryo PGT samples. 613 Table S4. The list of candidate SNPs. Table S5. Nonsynonymous SNPs that are 614 independent significant SNPs or in LD (r2>0.6) with one of the independent significant 615 616 SNPs. Table S6. The reported genomic risk loci from GWAS catalog that were detected in our dataset. Table S7. A list of 166 mapped genes by positional, eQTL, and chromatin 617 618 interaction mappings. Table S8. Data sources of genome-wide mRNA expression in Preterm birth, infant disease and breast cancer. Table S9. A list of the 166 mapped genes 619 that were also identified by differentially expressed genes (DEGs) derived from 620 analyzing the genome-wide gene expression datasets listed. 621

622 Additional file 2: Supplemental Methods

623 Additional file 3: Figure S1. Sequencing coverage statistics of the 17,844 embryos.

624 **Figure S2.** Visualizing the linear regression model for genotype accuracy prediction.

Figure S3. Quality control of SNP calling. Figure S4. Figure S4. Principal component

analysis of all 17,844 embryo samples. Figure S5. Distribution of gestational age in the

627	1,744 born embryo samples. Figure S6. Quantile-Quantile plot of the 1,107,198 studied
628	SNPs. Figure S7. Pie charts of the candidate SNPs. Figure S8. Zoom in locus plots of
629	the 11 genomic risk loci. Figure S9. Circos plots of chromatin interactions and eQTL
630	mapping. Figure S10. Gene set analysis of the 166 mapped genes. Figure 11. Co-
631	expression network of PTB-related genes in maternal and infant subtypes.
632	
633	Abbreviations
634	WGS: whole genome sequencing; NGS: next-generation sequencing; GWAS:
635	genome-wide association study; bp: base pair; SNP: single nucleotide polymorphism;
636	PTB: preterm birth; PGT: preimplantation genetic testing; MAF: minor allele
637	frequency; LD: linkage disequilibrium; HWE: Hardy-Weinberg equilibrium; WGA:
638	whole genome amplification; PCA: principal component analysis; eQTL: expression
639	quantitative trait locus; FDR: false discovery rate; GO: gene ontology; BPD:
640	bronchopulmonary dysplasia; ER: Estrogen receptor; PR: Progesterone receptor;
641	HER2: human epidermal growth factor receptor 2; TNBC: Triple-negative breast
642	cancer; DEG: differentially expressed gene; AF: allele frequency. GIAB: Genome in a
643	Bottle; BWA: Burrows-Wheeler Aligner. GEO: Gene Expression Omnibus: NCBI:
644	National Center for Biotechnology Information.
645	
646	Declarations
647	Ethics approval and consent to participate

All individual samples in the technical concordance cohort and clinical cohort, andprotocols used in this study have been reviewed and approved by the Institutional

650	Review Board (IRB) of China International Trust Investment Corporation - Xianngya
651	(IRB Reference No. LL-SC-2020-004). The need to obtain informed consent has been
652	waived by the IRB due to the study's retrospective nature. Following the regulations of
653	the Human Genetic Resources Administration of China, all genetic materials involved
654	in this study have been reviewed and approved by Ministry of Science and Technology
655	of the People's Republic of China (Approval No. [2022] GH1831). The experimental
656	methods were in accordance with the principles of the Helsinki Declaration.
657	
658	Consent for publication
659	Not applicable
660	
661	Availability of data and materials
661 662	Availability of data and materials The datasets supporting the conclusions of this article are included within the article
661 662 663	Availability of data and materials The datasets supporting the conclusions of this article are included within the article and its additional files. The significant SNPs and candidate SNPs are listed in
<ul><li>661</li><li>662</li><li>663</li><li>664</li></ul>	Availability of data and materials The datasets supporting the conclusions of this article are included within the article and its additional files. The significant SNPs and candidate SNPs are listed in Additional file 1: Tables S3 and S4, respectively. The processed or raw counts of mRNA
<ul><li>661</li><li>662</li><li>663</li><li>664</li><li>665</li></ul>	Availability of data and materials The datasets supporting the conclusions of this article are included within the article and its additional files. The significant SNPs and candidate SNPs are listed in Additional file 1: Tables S3 and S4, respectively. The processed or raw counts of mRNA expression datasets shown in Additional file 1: Table S8 was downloaded from Gene
<ul> <li>661</li> <li>662</li> <li>663</li> <li>664</li> <li>665</li> <li>666</li> </ul>	Availability of data and materials The datasets supporting the conclusions of this article are included within the article and its additional files. The significant SNPs and candidate SNPs are listed in Additional file 1: Tables S3 and S4, respectively. The processed or raw counts of mRNA expression datasets shown in Additional file 1: Table S8 was downloaded from Gene Expression Omnibus (GEO)/National Center for Biotechnology Information (NCBI).
<ul> <li>661</li> <li>662</li> <li>663</li> <li>664</li> <li>665</li> <li>666</li> <li>667</li> </ul>	Availability of data and materials The datasets supporting the conclusions of this article are included within the article and its additional files. The significant SNPs and candidate SNPs are listed in Additional file 1: Tables S3 and S4, respectively. The processed or raw counts of mRNA expression datasets shown in Additional file 1: Table S8 was downloaded from Gene Expression Omnibus (GEO)/National Center for Biotechnology Information (NCBI).
<ul> <li>661</li> <li>662</li> <li>663</li> <li>664</li> <li>665</li> <li>666</li> <li>667</li> <li>668</li> </ul>	Availability of data and materials The datasets supporting the conclusions of this article are included within the article and its additional files. The significant SNPs and candidate SNPs are listed in Additional file 1: Tables S3 and S4, respectively. The processed or raw counts of mRNA expression datasets shown in Additional file 1: Table S8 was downloaded from Gene Expression Omnibus (GEO)/National Center for Biotechnology Information (NCBI). Funding
<ul> <li>661</li> <li>662</li> <li>663</li> <li>664</li> <li>665</li> <li>666</li> <li>667</li> <li>668</li> <li>669</li> </ul>	Availability of data and materials The datasets supporting the conclusions of this article are included within the article and its additional files. The significant SNPs and candidate SNPs are listed in Additional file 1: Tables S3 and S4, respectively. The processed or raw counts of mRNA expression datasets shown in Additional file 1: Table S8 was downloaded from Gene Expression Omnibus (GEO)/National Center for Biotechnology Information (NCBI). Funding The study was supported by the Early Career Schema (27204518) of the Hong Kong
<ul> <li>661</li> <li>662</li> <li>663</li> <li>664</li> <li>665</li> <li>666</li> <li>667</li> <li>668</li> <li>669</li> <li>670</li> </ul>	Availability of data and materials The datasets supporting the conclusions of this article are included within the article and its additional files. The significant SNPs and candidate SNPs are listed in Additional file 1: Tables S3 and S4, respectively. The processed or raw counts of mRNA expression datasets shown in Additional file 1: Table S8 was downloaded from Gene Expression Omnibus (GEO)/National Center for Biotechnology Information (NCBI). Funding The study was supported by the Early Career Schema (27204518) of the Hong Kong Research Grants Council for RL, partially by General Research Funding of Hong Kong

672	Grants Committees Fund from the University of Hong Kong for RL, partially by
673	National Key Research and Developmental Program of China (2018YFC1004900) for
674	YT, by the Innovation and Technology Fund (ITF/331/17FP) of Innovation and
675	Technology Commission of the Hong Kong SAR government for TL.
676	
677	Competing interests
678	The authors declare that they have no competing interests.
679	
680	Authors' contributions
681	SL, RL and BY developed the computational pipeline and the algorithms. RL, GL, YW,
682	TKL, and TL designed the experiments. PX, YG, FG and YT contributed to the clinical
683	data collection. SL, BY, JL, YG and FG performed data processing and analysis. RL,
684	GL, SL, BY, PX and YW participated in drafting the manuscript. All authors read and
685	approved the final manuscript.
686	
687	Acknowledgements
688	Not applicable
689	
690	
691	
692	

#### 693 **Reference**

1. Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy MI, Brown MA, et al. 10
Years of GWAS Discovery: Biology, Function, and Translation. American journal of
human genetics. 2017;101(1):5-22.

Pasaniuc B, Rohland N, McLaren PJ, Garimella K, Zaitlen N, Li H, et al. Extremely
low-coverage sequencing and imputation increases power for genome-wide association
studies. 2012;44(6):631.

- 3. Wang Z, Chatterjee N. Increasing mapping precision of genome-wide association
  studies: to genotype and impute, sequence, or both? Genome Biology. 2017;18(1):118.
- 4. Quick C, Anugu P, Musani S, Weiss ST, Burchard EG, White MJ, et al. Sequencing
  and imputation in GWAS: Cost-effective strategies to increase power and genomic
  coverage across diverse populations. 2020;44(6):537-49.

5. Gilly A, Southam L, Suveges D, Kuchenbaecker K, Moore R, Melloni GEM, et al.
Very low-depth whole-genome sequencing in complex trait association studies.
Bioinformatics. 2019;35(15):2555-61.

6. Homburger JR, Neben CL, Mishne G, Zhou AY, Kathiresan S, Khera AV. Low coverage whole genome sequencing enables accurate assessment of common variants and calculation of genome-wide polygenic scores. Genome medicine. 2019;11(1):74.

711 7. Marchini J, Howie B. Genotype imputation for genome-wide association studies.
712 Nature reviews Genetics. 2010;11(7):499-511.

8. Liu S, Huang S, Chen F, Zhao L, Yuan Y, Francis SS, et al. Genomic Analyses from
Non-invasive Prenatal Testing Reveal Genetic Associations, Patterns of Viral Infections,
and Chinese Population History. Cell. 2018;175(2):347-59.e14.

- 716 9. Cronin FM, Segurado R, McAuliffe FM, Kelleher CC, Tremblay RE. Gestational
  717 Age at Birth and 'Body-Mind' Health at 5 Years of Age: A Population Based Cohort
  718 Study. PloS one. 2016;11(3):e0151222.
- 10. Knijnenburg TA, Vockley JG, Chambwe N, Gibbs DL, Humphries C, Huddleston
   KC, et al. Genomic and molecular characterization of preterm birth. Proceedings of the
- National Academy of Sciences of the United States of America. 2019;116(12):5819-27.
- 11. Liu X, Helenius D, Skotte L, Beaumont RN, Wielscher M, Geller F, et al. Variants
- in the fetal genome near pro-inflammatory cytokine genes on 2q13 associate with gestational duration. Nature communications. 2019;10(1):3927.

724 gestational duration. Nature communications. 2019;10(1):3927.

- 12. Zhang G, Feenstra B, Bacelis J, Liu X, Muglia LM, Juodakis J, et al. Genetic
  Associations with Gestational Duration and Spontaneous Preterm Birth. The New
  England journal of medicine. 2017;377(12):1156-67.
- 13. Wadon M, Modi N, Wong HS, Thapar A, O'Donovan MC. Recent advances in thegenetics of preterm birth. Annals of human genetics. 2019.
- 730 14. Brezina PR, Kutteh WH, Bailey AP, Ke RW. Preimplantation genetic screening
- 731 (PGS) is an excellent tool, but not perfect: a guide to counseling patients considering
- 732 PGS. Fertil Steril. 2016;105(1):49-50.
- 15. Huang L, Bogale B, Tang Y, Lu S, Xie XS, Racowsky C. Noninvasive
  preimplantation genetic testing for aneuploidy in spent medium may be more reliable

than trophectoderm biopsy. Proc Natl Acad Sci U S A. 2019;116(28):14105-12.

- 16. Tan Y, Yin X, Zhang S, Jiang H, Tan K, Li J, et al. Clinical outcome of preimplantation genetic diagnosis and screening using next generation sequencing.
- 738 GigaScience. 2014;3(1):30.
- 739 17. Zook JM, Chapman B, Wang J, Mittelman D, Hofmann O, Hide W, et al.
- 740 Integrating human sequence data sets provides a resource of benchmark SNP and indel
- 741 genotype calls. Nature Biotechnology. 2014;32(3):246-51.
- 742 18. Quinlan AR. BEDTools: The Swiss-Army Tool for Genome Feature Analysis.
  743 Current protocols in bioinformatics. 2014;47:11.2.1-34.
- 19. Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler
  transform. Bioinformatics. 2009;25(14):1754-60.
- 20. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence
  Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078-9.
- 21. Li H. FermiKit: assembly-based variant calling for Illumina resequencing data.
  Bioinformatics. 2015;31(22):3694-6.
- Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The
  human genome browser at UCSC. Genome Res. 2002;12(6):996-1006.
- 752 23. Kent WJ, Zweig AS, Barber G, Hinrichs AS, Karolchik D. BigWig and BigBed:
  753 enabling browsing of large distributed datasets. Bioinformatics. 2010;26(17):2204-7.
- 754 24. Davies RW, Flint J, Myers S, Mott R. Rapid genotype imputation from sequence
- 755 without reference panels. Nature genetics. 2016;48(8):965-9.
- 25. Skotte L, Korneliussen TS, Albrechtsen A. Association testing for next-generation
  sequencing data using score statistics. Genet Epidemiol. 2012;36(5):430-7.
- 26. Korneliussen TS, Albrechtsen A, Nielsen R. ANGSD: Analysis of Next Generation
  Sequencing Data. BMC Bioinformatics. 2014;15:356.
- 760 27. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and
  761 annotation of genetic associations with FUMA. Nature communications.
  762 2017;8(1):1826.
- 28. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A
  global reference for human genetic variation. Nature. 2015;526(7571):68-74.
- 765 29. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic
- variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.
  20. Sharman DT, Hao M, Oira L, Jiao X, Davalan MW, Lang HG, et al. DAVID: a such as the second s
- 30. Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, et al. DAVID: a web
  server for functional enrichment analysis and functional annotation of gene lists
  (2021 update). Nucleic Acids Res. 2022.
- 31. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45(6):580-5.
- 32. Schmitt AD, Hu M, Jung I, Xu Z, Qiu Y, Tan CL, et al. A Compendium of
- 772 Chromatin Contact Maps Reveals Spatially Active Regions in the Human Genome. Cell
- reports. 2016;17(8):2042-59.
- 33. Giusti-Rodriguez PM, Sullivan PF. Using three-dimensional regulatory chromatin
  interactions from adult and fetal cortex to interpret genetic results for psychiatric
  disorders and cognitive traits. 2019:406330.
- 34. Akbarian S, Liu C, Knowles JA, Vaccarino FM, Farnham PJ, Crawford GE, et al.
- The PsychENCODE project. Nature neuroscience. 2015;18(12):1707-12.

35. Noguchi S, Arakawa T, Fukuda S, Furuno M, Hasegawa A, Hori F, et al.
FANTOM5 CAGE profiles of human and mouse samples. Scientific data.
2017;4:170112.

- 782 36. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation
- method for the next generation of genome-wide association studies. PLoS Genet.2009;5(6):e1000529.
- 785 37. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP:
- the NCBI database of genetic variation. Nucleic Acids Res. 2001;29(1):308-11.
- 787 38. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The
- mutational constraint spectrum quantified from variation in 141,456 humans. Nature.
  2020;581(7809):434-43.
- 39. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than
  replication-based analysis for two-stage genome-wide association studies. Nat Genet.
  2006;38(2):209-13.
- 40. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, et al. LD
  Score regression distinguishes confounding from polygenicity in genome-wide
  association studies. Nat Genet. 2015;47(3):291-5.
- 796 41. Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang H, et al.
- Systematic localization of common disease-associated variation in regulatory DNA.
  Science. 2012;337(6099):1190-5.
- 42. Pasaniuc B, Rohland N, McLaren PJ, Garimella K, Zaitlen N, Li H, et al. Extremely
- low-coverage sequencing and imputation increases power for genome-wide association
   studies. Nature Genetics. 2012;44:631.
- 43. Wulf G, Ryo A, Liou Y-C, Lu KP. The prolyl isomerase Pin1 in breast development
  and cancer. Breast Cancer Res. 2003;5(2):76-82.
- 44. Consortium GT. The GTEx Consortium atlas of genetic regulatory effects across
  human tissues. Science (New York, NY). 2020;369(6509):1318-30.
- 45. Vora B, Wang A, Kosti I, Huang H, Paranjpe I, Woodruff TJ, et al. Meta-Analysis
- of Maternal and Fetal Transcriptomic Data Elucidates the Role of Adaptive and Innate
  Immunity in Preterm Birth. Front Immunol. 2018;9:993-.
- 809 46. Strauss JF, 3rd, Romero R, Gomez-Lopez N, Haymond-Thornburg H, Modi BP,
- Teves ME, et al. Spontaneous preterm birth: advances toward the discovery of genetic predisposition. American journal of obstetrics and gynecology. 2018;218(3):294-314.e2.
- 47. Velez DR, Fortunato SJ, Thorsen P, Lombardi SJ, Williams SM, Menon R. Preterm
  birth in Caucasians is associated with coagulation and inflammation pathway gene
- 815 variants. PloS one. 2008;3(9):e3283-e.
- 48. Sheikh IA, Ahmad E, Jamal MS, Rehan M, Assidi M, Tayubi IA, et al. Spontaneous
  preterm birth and single nucleotide gene polymorphisms: a recent update. BMC
- 818 Genomics. 2016;17(Suppl 9):759.
- 49. Uzun A, Sharma S, Padbury J. A bioinformatics approach to preterm birth.
  American journal of reproductive immunology (New York, NY : 1989).
  2012;67(4):273-7.
- 50. Siffel C, Kistler KD, Lewis JFM, Sarda SP. Global incidence of bronchopulmonary

823 dysplasia among extremely preterm infants: a systematic literature review. The journal

- 824 of maternal-fetal & neonatal medicine : the official journal of the European Association
- of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the
- 826 International Society of Perinatal Obstet. 2019:1-11.
- 51. Cai Y, Ma F, Qu L, Liu B, Xiong H, Ma Y, et al. Weighted Gene Co-expression
- 828 Network Analysis of Key Biomarkers Associated With Bronchopulmonary Dysplasia.
- 829 Front Genet. 2020;11:539292.
- 830 52. Villamor-Martinez E, Lubach GA, Rahim OM, Degraeuwe P, Zimmermann LJ,
- 831 Kramer BW, et al. Association of Histological and Clinical Chorioamnionitis With
- Neonatal Sepsis Among Preterm Infants: A Systematic Review, Meta-Analysis, and
  Meta-Regression. Front Immunol. 2020;11:972.
- 53. Rosette C, Roth RB, Oeth P, Braun A, Kammerer S, Ekblom J, et al. Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis. 2005;26(5):943-50.
- 54. Schroder C, Witzel I, Muller V, Krenkel S, Wirtz RM, Janicke F, et al. Prognostic
- value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer. J
  Cancer Res Clin Oncol. 2011;137(8):1193-201.
- 839 55. Xu WH, Liu ZB, Yang C, Qin W, Shao ZM. Expression of dickkopf-1 and beta-
- catenin related to the prognosis of breast cancer patients with triple negative phenotype.
  PloS one. 2012;7(5):e37624.
- 56. Shin E, Lee Y, Koo JS. Differential expression of the epigenetic methylationrelated protein DNMT1 by breast cancer molecular subtype and stromal histology. J
  Transl Med. 2016;14:87.
- 57. Wong KK. DNMT1: A key drug target in triple-negative breast cancer. SeminCancer Biol. 2020.
- 58. Robertson SA, Hutchinson MR, Rice KC, Chin PY, Moldenhauer LM, Stark MJ,
- et al. Targeting Toll-like receptor-4 to tackle preterm birth and fetal inflammatory injury.
  Clin Transl Immunology. 2020;9(4):e1121.
- 59. Zhang G, Srivastava A, Bacelis J, Juodakis J, Jacobsson B, Muglia LJ. Genetic
  studies of gestational duration and preterm birth. Best Pract Res Clin Obstet Gynaecol.
  2018;52:33-47.
- 60. Petraglia F, Imperatore A, Challis JR. Neuroendocrine mechanisms in pregnancyand parturition. Endocr Rev. 2010;31(6):783-816.
- 61. Majzoub JA, McGregor JA, Lockwood CJ, Smith R, Taggart MS, Schulkin J. A
- 856 central theory of preterm and term labor: putative role for corticotropin-releasing
- hormone. American journal of obstetrics and gynecology. 1999;180(1 Pt 3):S232-41.
- 62. Díaz-Pérez FI, Hiden U, Gauster M, Lang I, Konya V, Heinemann A, et al. Post-
- transcriptional down regulation of ICAM-1 in feto-placental endothelium in GDM. Cell
- adhesion & migration. 2016;10(1-2):18-27.
- 63. Chen X, Scholl TO. Maternal biomarkers of endothelial dysfunction and preterm
  delivery. PloS one. 2014;9(1):e85716.
- 64. Labarrere CA, Bammerlin E, Hardin JW, Dicarlo HL. Intercellular adhesion
   molecule-1 expression in massive chronic intervillositis: implications for the invasion
- of maternal cells into fetal tissues. Placenta. 2014;35(5):311-7.
- 866 65. Kim SC, Lee JE, Kang SS, Yang HS, Kim SS, An BS. The regulation of oxytocin

and oxytocin receptor in human placenta according to gestational age. Journal of molecular endocrinology. 2017;59(3):235-43. 66. Keyser EA, Staat BC, Fausett MB, Shields AD. Pregnancy-associated breast cancer. Rev Obstet Gynecol. 2012;5(2):94-9. 67. Froehlich K, Schmidt A, Heger JI, Al-Kawlani B, Aberl CA, Jeschke U, et al. Breast cancer, placenta and pregnancy. Eur J Cancer. 2019;115:68-78. 

# 906 Figures



907

908 Fig. 1. An overview of the analysis and benchmarking pipeline for ultra-low

909 coverage WGS.



910

911

Fig. 2. Imputation accuracy at different coverages and sample sizes. The accuracies of imputed genotype (a) or allele (b) were obtained by comparing with the known genotypes in HG005. After using filter "INFO score  $\ge 0.4$  and HWE *p*-value > 1e-6",

915 the accuracies of imputed genotype (c) or allele (d).



- 917
- 918

Fig. 3. Performance of different imputation result filters. The accuracies of our samples were calculated against the known genotypes in HG005. a, effect of INFO score filtering cutoffs on genotype and allele accuracies. The imputation was conducted by using 0.04x sequencing coverage of HG005 and with 16000 embryo samples. b, effect of MAF cutoffs on genotype accuracy at multiple sequencing coverages. The imputation was conducted through different sequencing coverages of HG005 with 16000 embryo samples.



927

928

Fig. 4. SNP-based genome-wide association on gestational age. a, Manhattan plot of 929 the SNPs in GWAS. The red dash line represents the genome-wide significance level 930 4.515e-8. The SNP "rs946934582" with p value of 2.764e-144 is beyond the scale, thus 931 hereby listed alone. The genes shown are linking with the candidate SNPs and position 932 of the corresponding genomic risk loci. b, functional annotation and enrichment test 933 result of the candidate SNPs in FUMA. c, a Venn diagram of the 166 genes that could 934 be mapped to the 11 genomic risk loci by positional, eQTL and chromatin interaction 935 strategies. d, a Circos plot of the chromatin interactions and eQTL mapping in the 11 936 genomic risk loci from eight chromosomes. The outer ring is chromosomes, the regions 937 in blue denote genomic risk loci. The middle ring represents the mapped genes. The 938 color of the gene symbols shows how they were mapped, eQTL in green, chromatin 939 940 interaction in orange, and both eQTL and chromatin interaction in black. The inner ring shows the linking edges, eQTL in green, and chromatin interaction in orange. e, a 941 summary of the 11 genomic risk loci. 942





Fig. 5. Comparison of the 166 genes mapped to 11 genomic risk loci with PTB and 945 946 infant disease. a, the 166 mapped genes were compared with 3 sets of reported PTB 947 genes including dbPTB from Sheikh et al. (48) and Uzun et al (49), PTB-merged from 5 resources (10), and PNAS-identified DEGs in 2019 (10) (see Additional file 1: Table 948 949 S8). b, a bar graph showing significantly enriched GO biological processes and KEGG pathways based on the 50 PTB marker genes (see Additional file 1: Table S7). c-d, 950 heatmaps showing expression profiling and clusters of the PTB genes predicted from 951 GWAS under maternal PTB (c) and PTB infant with BPD and sepsis (d). The gene 952 expression data was extracted from the listed GSE accession numbers of NCBI/GEO. 953



954

955

Fig. 6. Associated analysis of the PTB-related genes in maternal and infant 956 subtypes. a, a gene co-expression network merging maternal and infant PTB subtypes. 957 b, a gene co-expression network merging maternal PTB and BPD of preterm infant. In 958 959 A and B, oval nodes represent PTB related genes predicted from GWAS using the 1,744 born embryo samples, rectangle nodes refer to the 50 top PTB markers summarized 960 from previously studies (Additional file 1: Table S7), involving immune or 961 inflammation (blue), apoptosis (yellow), angiogenesis (green), coagulation (purple) and 962 other biological processes (grey). Co-expressive edges (Pearson correlation p value < 963 0.01) linking nodes represent maternal (red), infant (blue) and both maternal and infant 964 965 (black). c, a graphic summary to illustrate gestational age's association with PTB, infant disease and breast cancer. 966

967

969 Table 1. Genotype imputation performance with different filtering criteria

970

Filtering criteria	SNP number	Genotype accuracy	Allele accuracy
None	167814	0.584	0.758
Known SNP in 1000G reference panel	141161	0.578	0.751
INFO score $\geq 0.1$	156835	0.591	0.771
INFO score $\geq 0.2$	126331	0.618	0.794
INFO score $\geq 0.3$	84932	0.656	0.815
INFO score $\geq 0.4$	48176	0.7	0.834
$MAF \ge 0.05$	162788	0.597	0.777
HWE $p$ -value > 1e-9	84237	0.595	0.695
HWE <i>p</i> -value > 1e-6	77419	0.596	0.692
HWE $p$ -value > 1e-3	65561	0.599	0.687
HWE <i>p</i> -value > 1e-6 and INFO score $\ge 0.1$	68505	0.610	0.713
HWE <i>p</i> -value > 1e-6 and INFO score $\ge 0.2$	55972	0.646	0.751
HWE <i>p</i> -value > 1e-6 and INFO score $\ge 0.3$	42202	0.681	0.786
HWE <i>p</i> -value > 1e-6 and INFO score $\ge 0.4$	28773	0.715	0.818

971 Totally 16,000 samples with an average of 0.04x sequencing coverage were used for imputation.

# Table 2. Main mapped genes differentially expressed in PTB, infant disease and breast cancer

975

Genes	Overlapped No. No. of DEGs detected in gene expression data							
mapped	with the reported	Maternal	Infant PTB	Infant	Infant	Breast cancer	Breast cancer	Breast cancer
to risk	PTB datasets	PTB		BPD	sepsis	ER, PR	TNBC	HER2+
loci								
ICAM1	6	1(up)	2(up)	1(up)	1(up)	1(up),2(down)	2(up)	1(up)
CRHBP	5	2(up)	1(up)	1(up)				
OXTR	5	2(up)				1(up)	1(down)	
THBS4	3	1(down)	1(down)		1(up)	1(up)	2(down)	1(up),1(down)
EGR2	2	1(up)	1(up)	1(up)		1(up)	2(down)	2(down)
CNTLN	1	1(up)	1(up),1(down)		1(up)	1(down)		1(down)
MBL2	4		1(up)					
EMR1	2			1(up)				
PLAGL1	1	1(up)	2(up)		1(up)	2(down)	2(down)	2(down)
DKK1		2(up)	1(up)	1(down)		2(down)	3(up),1(down)	1(up),1(down)
GCNT4		1(down)	2(down)	1(down)	2(down)	1(up),2(down)	1(down)	1(down)
DNMT1		1(up)	1(up)				1(up)	1(up)
PIN1		1(down)	1(down)					

976 PTB related genes identified in our GWAS were compared with DEGs identified in published gene
977 expression datasets (Additional file 1: Table S9). "up" and "down" indicate differentially overexpressed
978 and underexpressed gene, respectively.

<sup>972</sup>